TY - JOUR T1 - Humoral immune response in inactivated SARS-CoV-2 vaccine: When should a booster dose be administered? JF - medRxiv DO - 10.1101/2021.07.08.21260194 SP - 2021.07.08.21260194 AU - Ertan Kara AU - Ferdi Tanir AU - Hakan Demirhindi AU - Burak Mete AU - Filiz Kibar AU - Salih Cetiner AU - Aslihan Candevir AU - Ayşe Inaltekin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/13/2021.07.08.21260194.abstract N2 - Background For a sustained and essential protective antibody response, it is important to understand how long the humoral immune response induced by the SARS-CoV-2 inactivated vaccine persists.Aims This study aimed to detect the first and third-month concentrations and seroconversion rates of the antibodies induced by the inactivated vaccine.Study Design This is a vaccine efficacy study.Methods The study included 272 health workers who were vaccinated at days 0 and 28 by the inactivated SARS-CoV-2 vaccine (3μg/0.5ml). Anti-S-RBD-IgG and total anti-spike/anti- nucleocapsid-IgG antibody concentrations and seroconversion rates were examined in vaccinated health workers at the 1st and 3rd months after the vaccination. The test method used for the qualitative detection and differentiation of IgG antibodies (indirect method) to SARS-CoV-2 is a chemiluminescence reaction (CLIA).Results The mean age of the health workers was 38.93±10.59 (min:21-max:64). A total of 45(16.5%) participants declared to have had COVID-19 before the first dose of the inactivated vaccine. The participants were found to be reactive for anti-S-RBD-IgG antibodies by 98.2% and 97.8% at the first and third months, respectively, after the administration of the second dose. The decrease in the mean plasma concentrations of anti-S-RBD IgG was observed as 56.7% in the cohort with only two doses of the vaccine (1st month:42.4AU/ml versus 3rd month: 18.2AU/ml). In the cohort with a history of COVID-19 prior to the vaccination, the decrease was observed as 25.1% (1st month:58.29 versus 3rd month:43.64 AU/ml) and at a mean of 57.4 (0-90) days prior to vaccination, the decrease was of 43.1% (1st month:55.05 AU/ml versus 3rd month:31.28 AU/ml), keeping more stable in participants infected at a mean of 183.1 (91-330) days prior to vaccination (a decrease of 5.2%; with 62.34 AU/ml at 1st and 59.08 AU/ml at 3rd months). Anti-S-RBD concentrations were observed to increase 10-fold (30.44 AU/ml at 1st and 310.64 AU/ml at 3rd months) in participants infected after the vaccination and to decrease among people aged 50 years and older.Conclusion Antibody concentrations at the 1st and 3rd months after the vaccination with two doses of the inactivated SARS-CoV-2 vaccine were found to be decreased, but still detectable (except in one participant). As participants who had COVID-19 at a mean of 181 (90-330) days before the vaccination presented with a more stable antibody level, it can be concluded that a booster at months 6-12, resulting in a schedule of 0-1-6 months, is recommended for the inactive SARS-CoV-2 vaccination.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThe project was supported by the Scientific Research Projects Office of the University of Cukurova, Turkey (Project ID: TSA-2021-13677)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by (1)The Scientific Research Platform of the Turkish Ministry of Health and (2) the Scientific Ethics Committee for Non-interventional Clinical Studies of the Cukurova University Faculty of Medicine (Adana, Turkey) (Decree no. 36, Meeting No. 108, 12.02.2021). The official invitation letters with the list of the randomly selected participants and substitutions were sent to the department headships in order to let them invite the selected staff to participate in the study. Informed written consents were obtained from all participants after required acknowledgement.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a vaccine efficacy study and not a clinical study. Data available on request from the authors. ER -